(Q39254901)

10 September 2017

title

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells (English)

1 reference

10 September 2017

3

1 reference

10 September 2017

Anna-Maria Jegg

1

1 reference

10 September 2017

Toby M Ward

2

1 reference

10 September 2017

Nicholas Hoe

4

1 reference

10 September 2017

Jinyao Zhou

5

1 reference

10 September 2017

Xiaofei Liu

6

1 reference

10 September 2017

Sharat Singh

7

1 reference

10 September 2017

Ralf Landgraf

8

1 reference

10 September 2017

Mark D Pegram

9

1 reference

10 September 2017

language of work or name

English

0 references

publication date

23 October 2012

1 reference

Breast Cancer Research and Treatment

10 September 2017

published in

1 reference

10 September 2017

volume

136

1 reference

10 September 2017

issue

3

1 reference

10 September 2017

page(s)

683-692

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-012-2252-9

10 September 2017

exact match

0 references

cites work

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Assessment of the Alamar Blue assay for cellular growth and viability in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Signaling via Shc family adapter proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Identification of a proline-rich Akt substrate as a 14-3-3 binding partner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

AMPK phosphorylation of raptor mediates a metabolic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Rheb promotes cell growth as a component of the insulin/TOR signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

The PTEN-PI3K pathway: of feedbacks and cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2252-9

10.1007/S10549-012-2252-9

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference